Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.57 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.57 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.57 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227695 | 1.00 | CSNK1A1 (0.57) | CSNK1A1TYRO3DYRK1BBCAT2GRM5 | |
| SCHEMBL38656817 | 0.84 | CSNK1A1 (0.50) | CSNK1A1TYRO3DYRK1BBCAT2GRM5 | |
| SCHEMBL9592605 | 0.83 | PARP1 (0.50) | CSNK1A1TYRO3DYRK1BBCAT2GRM5 | |
| SCHEMBL1535154 | 0.83 | PARP1 (0.50) | CSNK1A1TYRO3DYRK1BBCAT2GRM5 | |
| SCHEMBL21777090 | 0.82 | CSNK1A1 (0.41) | CSNK1A1TYRO3DYRK1BBCAT2GRM5 | |
| SCHEMBL465563 | 0.82 | KDM4E (0.55) | NPC1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL32691840 | 0.81 | CSNK1A1 (0.48) | CSNK1A1TYRO3DYRK1BBCAT2GRM5 | |
| SCHEMBL997865 | 0.81 | GRM5 (0.64) | CSNK1A1TYRO3DYRK1BBCAT2GRM5 | |
| SCHEMBL31249984 | 0.81 | GRM5 (0.64) | CSNK1A1TYRO3DYRK1BBCAT2GRM5 | |
| SCHEMBL31249988 | 0.81 | GRM5 (0.64) | CSNK1A1TYRO3DYRK1BBCAT2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107898-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-12-28 | — | — | EP | claimed |
| WO-2015124932-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-08-27 | — | — | WO | claimed |
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12331029-B2 | Orexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-06-17 | — | — | US | disclosed |
| EP-3107898-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015124932-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015055994-A1 | CYCLOPENTYLBENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PSYCHOTIC AND COGNITIVE DISORDERS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
| CN-104203935-A | 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as GPBAR1 modulators | HOFFMANN LA ROCHE | 2014-12-10 | — | — | CN | disclosed |
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2003010153-A1 | N-ALKYL-N-PHENYLHYDROXYLAMINE COMPOUNDS CONTAINING METAL CHELATING GROUPS, THEIR PREPARATION AND THEIR THERAPEUTIC USES | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | LCK, BTK, IRAK1 | CSNK1A1 61/4885TYRO3 37/4885DYRK1B 664/4885 |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | LCK, BTK, IRAK1 | CSNK1A1 61/4885TYRO3 37/4885DYRK1B 664/4885 |
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | CNR1, CNR2, OPRM1 | CSNK1A1 939/4885TYRO3 655/4885DYRK1B 986/4885 |
| US-12331029-B2 | Orexin 1 receptor antagonists | HCRTR1, HCRTR2, NPY1R | CSNK1A1 1756/4885TYRO3 1358/4885DYRK1B 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.